ImmuneRegen's Radilex to be evaluated by the U.S. government as a possible terrorist countermeasure

By Lisa Kerner

Charlotte, N.C., July 24 - ImmuneRegen said the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (NIH), will conduct a preclinical evaluation of its proprietary compound Radilex for its use as a potential treatment for acute radiation syndrome (ARS).

In the study, the NIAID will evaluate the efficacy of Radilex in preventing or treating radiation sickness in an animal model and the possible use of Radilex as a medical countermeasure in a radiation/nuclear emergency, including a terrorist attack.

ImmuneRegen said these evaluations are funded as part of the NIH Radiation/ Nuclear Countermeasures Product Development Program.

The company is developing Radilex for possible use in connection with life-threatening conditions associated with ARS, including neutropenia and thrombocytopenia.

ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., is a development-stage biotechnology company based in Scottsdale, Ariz.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.